Medical Economics & Analytics Intern

New progyny study examines persistent racial and Ethnic differences in fertility treatment initiation despite access to benefits. Published on 10/28/2026 at 09:52 am EDT GlobeNewswire Research presented at ASRM 2026 Scientific Congress & Expo highlights the importance of early engagement and personalized support in helping patients navigate fertility care NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, today announced findings from new research presented at the American Society for Reproductive Medicine (ASRM) 2026 Scientific Congress & Expo, revealing that racial and ethnic disparities in fertility treatment initiation persist even among patients with access to fertility benefits. However, the time from initial consultation to the start of a treatment cycle resulting in pregnancy was largely comparable across racial and ethnic groups, highlighting the importance of better understanding the clinical, personal, and other factors that influence treatment decisions. The study, "Racial and Ethnic Disparities in Initiation of Treatment Within a Fertility Benefit Program," examined 12,516 patients who accessed fertility benefits between 2024 and 2025 to better understand how race and ethnicity may influence treatment initiation, time to care, treatment selection, and time to pregnancy. Key findings from the research include: * Disparities persist despite access to benefits. African American/Black, Asian/Pacific Islander, and Other/Mixed race and ethnicity patients had treatment initiation rates approximately 10%, 19%, and 11% lower, respectively, than White patients, despite access to fertility benefits. * Some patients experienced longer delays in starting treatment. African American/Black patients waited an average of 136 days between their initial fertility consultation and treatment initiation, while patients identifying as Other/Mixed race and ethnicity waited 144 days, compared to 127 days for White patients. This represents an additional 9 and 17 days, respectively. * Timing of treatment cycles resulting in pregnancy was largely comparable. The time from initial consultation to the start of a treatment cycle resulting in pregnancy ranged from 180 to 190 days across racial and ethnic groups, with relatively modest differences observed between groups. * Treatment pathways also varied. Asian/Pacific Islander patients had 23% higher adjusted odds of initiating intrauterine insemination (IUI) and 15% lower adjusted odds of initiating in vitro fertilization (IVF) compared to White patients. While IVF generally offers higher success rates per treatment cycle than IUI, the most appropriate treatment depends on each patient's unique clinical circumstances. These findings highlight the importance of understanding differences in treatment selection and ensuring patients have the guidance needed to make informed decisions about their care. "Expanding access to fertility benefits is an important step toward making care more equitable, but this research reminds us that coverage alone does not eliminate every barrier patients may face," said Janet Choi, MD, Chief Medical Officer, Progyny. "What stands out is that once patients engage in treatment, time to pregnancy is largely similar across groups. That reinforces the need to look more closely at the barriers that may inhibit certain patient populations from pursuing appropriate clinical evaluations as well as what obstacles may delay certain patient populations from proceeding to timely, indicated treatments even when they have access to comprehensive fertility benefits." As Progyny marks its 10th anniversary, the findings reinforce the company's longstanding commitment to advancing fertility care through research, innovation, and personalized support. The study underscores the importance of looking beyond coverage to better understand the factors that influence whether and when patients begin fertility treatment. While the research did not evaluate the underlying reasons for differences in treatment initiation, clinical indications, patient preferences, decisions to defer treatment, and potential barriers to care may all play a role. Further research is needed to better understand these differences and identify opportunities to support informed, individualized treatment decisions. "Improving fertility care requires us to understand not only what happens during treatment, but also who is getting to treatment in the first place," said Kyle Le, MD, a Reproductive Endocrinology and Infertility (REI) fellow at Shady Grove Fertility who presented the research at ASRM. "These findings highlight the importance of looking more closely at differences in treatment decisions across patient populations and identifying opportunities to ensure every individual receives appropriate, personalized care." The research was conducted by investigators affiliated with Shady Grove Fertility - Jones Institute at EVMS/ODU, Icahn School of Medicine at Mount Sinai, Progyny, and Reproductive Medicine Associates (RMA) of New York. To learn more about Progyny's fertility research and clinical outcomes, visit progyny.com/superior-outcomes. About Progyny Progyny is a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx(R), and personalized guidance from Progyny Care Advocates(R) to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com. For Further Information, Please Contact: Alexis Ford [email protected] Investors: James Hart [email protected] (C) GlobeNewswire - 2026

JPMorgan cuts target for Sotera Health stock from USD 18 to USD 17. Published on 10/20/2026 at 18:58 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS Second-quarter revenue reached USD 321.38 million on June 30, 2026. Sotera Health stock costs EUR 16.00 on October 20, 2026 at 6:48 p.m. CEST. Analyst target and reporting date. * JPMorgan cut its Sotera Health target from USD 18.00 to USD 17.00 on October 14, 2026. * Second-quarter revenue reached USD 321.38 million for the period ended June 30, 2026. * Sotera Health stock was at EUR 16.00 at Lang & Schwarz on October 20, 2026 at 6:48 p.m. CEST. * The company is scheduled to report third-quarter 2026 results on November 3, 2026. Sotera Health stock became the subject of a JPMorgan downgrade on October 14, 2026, when the bank moved its rating from Neutral to Underweight and cut its target from USD 18.00 to USD 17.00, as Markets Insider reported. At Lang & Schwarz, the stock was trading at EUR 16.00 on October 20, 2026 at 6:48 p.m. CEST. Discover more Hire M&A Advisors Invest in Stocks Revenue growth remains visible. The company reported second-quarter 2026 revenue of USD 321.38 million for the period ended June 30, 2026, up 9.20 percent from the prior-year quarter. Net income reached USD 53.64 million, or USD 0.19 per diluted share, compared with USD 8.00 million and USD 0.03 per diluted share in the second quarter of 2025, according to Sotera Health. Stock position and valuation. The Nasdaq quote stood at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. Sotera Health had a market capitalization of USD 5.1 billion and a trailing price-to-earnings ratio of 31.43 at that timestamp. Its 52-week range was USD 13.09 to USD 19.85, placing the quote 9.42 percent below the high and 37.36 percent above the low. Trading volume reached 590,875 shares. Target and reporting date matter. JPMorgan's USD 17.00 target stood 5.45 percent below the Nasdaq price of USD 17.98 on October 20, 2026. The bank cited uncertainty around future volume growth and the medical device end market in its October 14 note, as Markets Insider reported. Sotera Health is scheduled to report third-quarter 2026 results on November 3, 2026, with consensus earnings per share of USD 0.24, according to MetaCap. Peer valuation stays mixed. Comparison with peers Progyny (Nasdaq, USD): down 2.17 percent, P/E 29.80, market capitalization USD 2.06 billion, according to MetaCap. DaVita (NYSE, USD): down 0.98 percent, P/E 15.80, market capitalization USD 11.95 billion, according to MetaCap. What the target signals. The lower JPMorgan target contrasts with Sotera Health's 9.20 percent second-quarter revenue growth and sets a clear test for the November results. Investors will have fresh operating figures to compare with the USD 17.00 target. On Nasdaq, the stock was trading at USD 17.98 on October 20, 2026 at 12:57 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of Sotera Health stock. Sotera Health at a glance. * Company: Sotera Health Company * ISIN: US83601L1026 * Ticker: SHC * Primary exchange: Nasdaq * Price Lang & Schwarz as of October 20, 2026, 6:48 p.m. CEST: EUR 16.00 * Market capitalization: USD 5.1 billion as of October 20, 2026 * 52-week range: USD 13.09-19.85 as of October 20, 2026 * Sector / Industry: Health Care / Miscellaneous Health and Biotechnology Services * Next earnings date: November 3, 2026 Discover more Compare Lab Gear Track Biotech Read Company News Sponsored Ad Sotera Health Co stock: new analysis - 23 October. Fresh Sotera Health Co information released. What's the impact for investors? Our latest independent report examines recent figures and market trends. Disclaimer regarding our articles: This is not investment advice, nor is it a recommendation to buy or sell. Information regarding prices, companies, and markets is provided without guarantee; changes may occur at any time. Stock market transactions can result in significant losses. Our articles are created and reviewed, in whole or in part, automatically with the assistance of AI. en | US83601L1026 | SHC | boerse | 70376329 | bgmi

Progyny to present new menopause research at The Menopause Society 2026 Annual Meeting. NEW YORK, Oct. 15, 2026 (GLOBE NEWSWIRE) - Progyny, Inc. (Nasdaq: PGNY), a global leader in women's health and family building solutions, announced today that it will present new research evaluating real-world outcomes from its Menopause and Midlife program and exhibit at The Menopause Society 2026 Annual Meeting in San Diego, October 20 - 24, 2026. As a leading provider of employer-sponsored menopause care around the globe, Progyny is committed to expanding access to high quality, evidence-based care and demonstrating its impact on women's health outcomes. The research, "Scaling Access to Menopause Care: Real-World Symptom Improvement in an Employer-Sponsored Program," will be presented by Gloria Richard-Davis, MD, MBA, Regional Dean at Morehouse School of Medicine, member of Progyny's Medical Advisory Board, and former Secretary and two-term member of The Menopause Society's Board of Trustees. The study was conducted in partnership with Morehouse School of Medicine and evaluated access, engagement, and changes in menopause symptoms among women participating in Progyny's employer-sponsored Menopause and Midlife program. "Menopause is a significant health transition, yet too many women still struggle to find clinicians with the expertise to provide individualized, evidence-based care," said Janet Choi, MD, Chief Medical Officer, Progyny. "This research demonstrates the potential to translate menopause expertise into a model that can reach more women and meaningfully improve their symptoms. That's an important step toward making high-quality menopause care a more accessible part of women's healthcare." Progyny's participation in The Menopause Society Annual Meeting reflects the company's continued expansion of its clinical research and solutions across the entire women's health spectrum. Building on more than a decade of experience in fertility and family building, Progyny now supports members across the reproductive health continuum, including preconception, fertility, pregnancy, postpartum, and menopause and midlife. Dr. Richard-Davis will present the research during Concurrent Session #2 on Thursday, October 22, from 5:15-5:30 PM PT. The Progyny team will be at Booth #211 if there is interest to learn more about its Menopause and Midlife program and broader women's health offerings. To learn more about Progyny's Menopause and Midlife offering, please visit Progyny.com/menopausesupport About Progyny Progyny is a global leader in women's health and family building solutions, trusted by leading employers, health plans, and benefit purchasers worldwide. Through its comprehensive and personalized approach, Progyny supports members across fertility and family building, pregnancy and postpartum, menopause and midlife, and parent and child well-being journeys. Progyny combines differentiated clinical care, integrated pharmacy support through Progyny Rx(R), and personalized guidance from Progyny Care Advocates(R) to deliver improved member experiences and better health outcomes. For more information, visit www.progyny.com. For Further Information, Please Contact: Alexis Ford Investors: James Hart Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. Military Industry Today do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.